Papers [Regulatives / Guidelines]

posted by Mahmoud  – Jordan, 2021-09-17 15:31 (947 d 02:06 ago) – Posting: # 22580
Views: 2,534

Dear all

Dr Anders Fuglsang discussed in his paper

Mitigation of the convergence issues associated with semi-replicated bioequivalence data. Pharmaceutical Statistics. 2021;1–3
used the proc mixed in RTR/TRR/RRT design in ABE

I think that using proc mixed to fit RTR/TRR/RRT design is not suitable, because in most cases proc mixed produced Estimated G matrix is not positive definite.

So proc GLM recommended by FDA and Emea is more appropriate in the Semi-replicated designs


Edit: Post moved. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,988 posts in 4,825 threads, 1,649 registered users;
22 visitors (0 registered, 22 guests [including 6 identified bots]).
Forum time: 17:37 CEST (Europe/Vienna)

As soon as we abandon our own reason, and are content
to rely upon authority, there is no end to our troubles.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz